Law firms Rising stars: David Gibson – ‘There are so many great new technologies and medicines with potential to make a difference to populations and treatment pathways but key challenges remain in regulating them’ Sophie Chan · 9 February 2024 · 3 min read Profile Life Sciences Yearbook 2024 McDermott Will & Schulte David Gibson, senior associate at McDermott Will & EmeryWhy did you decide to specialise in life sciences law, and what’s the best thing about being a life sciences lawyer?Your limit of 1 article in 30 days is up. Please login for full access or subscribe. Corporate users - click here for simple access (no password needed). For more information, please contact [email protected] Related ContentMore in this categoryRevolving Doors: Weil hires Kirkland secondaries partner as Orrick targets Cadwalader againLaw firmsKate Peacock14 Apr 2026Trading Places: Ropes hires Freshfields levfin co-head as top Kirkland litigator retiresLaw firmsEliza Winter25 Mar 2026Dechert posts 27% PEP hike as expansion drive continuesLaw firmsKate Peacock23 Mar 2026M&A perspectives: Melissa FogartyLaw firmsIman Tribak26 Jun 2024M&A perspectives: Jennifer BethlehemLaw firmsIman Tribak26 Jun 2024M&A perspectives: Lorenzo CorteLaw firmsIman Tribak26 Jun 2024Sponsored thought leadership: China life sciences – Transaction insights and notable industry trendsPractice areasGuest Blog9 Feb 2024The Legal 500 view: Healthy competitionLaw firmsBen Wheway9 Feb 2024Life Sciences Yearbook 2024 – Editor’s letterPractice areasGeorgina Stanley9 Feb 2024